Form 4: Enliven Therapeutics COO Anish Patel Sells Shares Under 10b5-1 Trading Plan

Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on May 7, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Anish Patel, the Chief Operating Officer of Enliven Therapeutics, sold shares of the company's common stock on May 7, 2025.
• The sales were executed under a Rule 10b5-1 trading plan adopted on September 30, 2024.
• A total of 6,667 shares were sold in multiple transactions at varying prices.
• The weighted average sale prices ranged from $18.2969 to $19.8719 per share.
• Following the reported transactions, Patel directly owns 6,173 shares and indirectly owns 309,976 shares through The Patel / Dong Family Trust.
• The shares held by The Patel / Dong Family Trust are managed by Patel as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports the sale of shares under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Sales by company insiders are a common occurrence and are often executed under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The market typically views these sales in the context of the insider's overall holdings and the reasons behind the sale (e.g., diversification, personal financial needs).

Comparison to Industry Standards

• Insider sales are a regular part of the stock market, with executives often using Rule 10b5-1 plans to sell shares periodically.
• Companies like Pfizer, Apple, and Microsoft see frequent insider trading activity, which is closely monitored by investors.
• The volume and frequency of these sales are compared against historical data and industry benchmarks to assess their significance.

Stakeholder Impact

• The sale of shares by a company executive could potentially create short-term negative sentiment among shareholders, although this is mitigated by the fact that the sales were pre-planned.
• The impact on other stakeholders (employees, customers, suppliers, creditors) is likely to be minimal.

Key Dates

Keywords

Form 4, Enliven Therapeutics, ELVN, Anish Patel, Rule 10b5-1, Share Sale, COO, Insider Trading